On November 21, Legend Biotech fell 5.09% in Regular Trading, trading at $15.28 per share, with turnover of $26.6822 million.
The move was accompanied by continued pressure from a more cautious sell-side stance after the company’s latest quarterly results, with Evercore ISI previously downgrading the stock to In Line and setting a $20 price target, contributing to weaker near-term growth and valuation expectations.
In the latest reported quarter, Legend Biotech posted net income of $51.7 million, reversing from a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million came in slightly below market expectations near $361.5 million, and several firms subsequently lowered target prices, indicating that improving profitability has not fully offset investor caution.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments